Unicycive Therapeutics, Inc. Q2 2026: Net income $(1.72M), EPS $(0.06) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Unicycive Therapeutics reported a Q2 2026 net loss of $1.72M, a significant improvement from the prior year's $6.45M loss, with diluted EPS at $(0.06). The company had no product revenue. On June 30, 2026, it received an FDA complete response letter for its OLC resubmission due to manufacturing deficiencies, though safety and efficacy were not questioned. Unicycive raised approximately $34M in H1 2026 via equity sales to support operations and clinical programs for the next 12+ months.
Unicycive Therapeutics, Inc. reported results for the quarter ended June 30, 2026, posting net income of $(1.72M), a significant improvement from a net loss of $(6.45M) in the year‑ago quarter; diluted EPS was $(0.06) versus $(0.52) in Q2 2025. The company did not report product revenue for the periods presented.
Financial Highlights
- Net income was $(1.72M) for Q2 2026 (three months ended June 30, 2026), improved vs. $(6.45M) in the year‑ago quarter — ~73% improvement YoY.
- Diluted earnings per share was $(0.06) for Q2 2026, versus $(0.52) in the year‑ago quarter.
- Revenue: Not reported for the periods presented in Part I, Item 1 (no product sales disclosed).
Business Highlights
- Regulatory: The company received an FDA complete response letter (CRL) for its OLC resubmission on June 30, 2026; the CRL cited a manufacturing deficiency while raising no safety or efficacy concerns.
- Clinical and development: UNI-494 Phase I completed in 2024; Unicycive continues to advance programs focused on hyperphosphatemia and acute kidney injury with ongoing development plans.
- Commercial readiness: The company increased commercial launch preparations and related G&A spending and is preparing supply chain and CMO engagements in anticipation of potential future launches.
- Funding and liquidity: Unicycive raised approximately $34M in net proceeds from at‑the‑market equity sales in H1 2026 to support operations and clinical programs for the next 12+ months.
Original SEC Filing: Unicycive Therapeutics, Inc. [ UNCY ] - 10-Q - Aug. 12, 2026